vs
Side-by-side financial comparison of ENNIS, INC. (EBF) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $100.2M, roughly 1.7× ENNIS, INC.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 0.4%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 1.4%).
ENNIS, INC. (ticker EBF) is a leading North American provider of printed business products and related services. Its offerings include custom business forms, pressure-sensitive labels, marketing collateral, promotional items, and branded packaging, serving clients across retail, healthcare, financial services, and small business segments.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
EBF vs ESPR — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $100.2M | $168.4M |
| Net Profit | $10.8M | — |
| Gross Margin | 31.9% | — |
| Operating Margin | 15.0% | 50.6% |
| Net Margin | 10.8% | — |
| Revenue YoY | 0.4% | 143.7% |
| Net Profit YoY | 6.1% | — |
| EPS (diluted) | $0.42 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $100.2M | $168.4M | ||
| Q3 25 | $98.7M | $87.3M | ||
| Q2 25 | $97.2M | $82.4M | ||
| Q1 25 | $92.7M | $65.0M | ||
| Q4 24 | $99.8M | $69.1M | ||
| Q3 24 | $99.0M | $51.6M | ||
| Q2 24 | $103.1M | $73.8M | ||
| Q1 24 | $97.4M | $137.7M |
| Q4 25 | $10.8M | — | ||
| Q3 25 | $13.2M | $-31.3M | ||
| Q2 25 | $9.8M | $-12.7M | ||
| Q1 25 | $9.0M | $-40.5M | ||
| Q4 24 | $10.2M | — | ||
| Q3 24 | $10.3M | $-29.5M | ||
| Q2 24 | $10.7M | $-61.9M | ||
| Q1 24 | $10.1M | $61.0M |
| Q4 25 | 31.9% | — | ||
| Q3 25 | 30.5% | — | ||
| Q2 25 | 31.1% | — | ||
| Q1 25 | 29.5% | — | ||
| Q4 24 | 29.3% | — | ||
| Q3 24 | 30.1% | — | ||
| Q2 24 | 30.0% | — | ||
| Q1 24 | 28.4% | — |
| Q4 25 | 15.0% | 50.6% | ||
| Q3 25 | 12.5% | -11.4% | ||
| Q2 25 | 13.7% | 8.6% | ||
| Q1 25 | 13.0% | -34.0% | ||
| Q4 24 | 13.1% | -6.4% | ||
| Q3 24 | 13.3% | -31.0% | ||
| Q2 24 | 13.3% | 3.5% | ||
| Q1 24 | 13.3% | 52.5% |
| Q4 25 | 10.8% | — | ||
| Q3 25 | 13.3% | -35.9% | ||
| Q2 25 | 10.1% | -15.4% | ||
| Q1 25 | 9.7% | -62.2% | ||
| Q4 24 | 10.2% | — | ||
| Q3 24 | 10.4% | -57.2% | ||
| Q2 24 | 10.4% | -83.9% | ||
| Q1 24 | 10.4% | 44.3% |
| Q4 25 | $0.42 | $0.32 | ||
| Q3 25 | $0.51 | $-0.16 | ||
| Q2 25 | $0.38 | $-0.06 | ||
| Q1 25 | $0.34 | $-0.21 | ||
| Q4 24 | $0.39 | $-0.14 | ||
| Q3 24 | $0.40 | $-0.15 | ||
| Q2 24 | $0.41 | $-0.33 | ||
| Q1 24 | $0.39 | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.3M | $167.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $304.8M | $-302.0M |
| Total Assets | $354.3M | $465.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.3M | $167.9M | ||
| Q3 25 | $31.9M | $92.4M | ||
| Q2 25 | $32.6M | $86.1M | ||
| Q1 25 | $72.5M | $114.6M | ||
| Q4 24 | $68.6M | $144.8M | ||
| Q3 24 | $122.6M | $144.7M | ||
| Q2 24 | $123.7M | $189.3M | ||
| Q1 24 | $110.9M | $226.6M |
| Q4 25 | $304.8M | $-302.0M | ||
| Q3 25 | $305.4M | $-451.4M | ||
| Q2 25 | $301.2M | $-433.5M | ||
| Q1 25 | $302.0M | $-426.2M | ||
| Q4 24 | $297.7M | $-388.7M | ||
| Q3 24 | $358.4M | $-370.2M | ||
| Q2 24 | $354.4M | $-344.2M | ||
| Q1 24 | $349.8M | $-294.3M |
| Q4 25 | $354.3M | $465.9M | ||
| Q3 25 | $361.8M | $364.0M | ||
| Q2 25 | $361.7M | $347.1M | ||
| Q1 25 | $348.9M | $324.0M | ||
| Q4 24 | $346.1M | $343.8M | ||
| Q3 24 | $406.8M | $314.1M | ||
| Q2 24 | $406.2M | $352.3M | ||
| Q1 24 | $399.2M | $373.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $16.4M | $45.2M |
| Free Cash FlowOCF − Capex | $15.7M | — |
| FCF MarginFCF / Revenue | 15.7% | — |
| Capex IntensityCapex / Revenue | 0.7% | 0.0% |
| Cash ConversionOCF / Net Profit | 1.52× | — |
| TTM Free Cash FlowTrailing 4 quarters | $42.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.4M | $45.2M | ||
| Q3 25 | $10.5M | $-4.3M | ||
| Q2 25 | $8.0M | $-31.4M | ||
| Q1 25 | $12.8M | $-22.6M | ||
| Q4 24 | $18.2M | $-35.0M | ||
| Q3 24 | $11.8M | $-35.3M | ||
| Q2 24 | $23.1M | $-7.2M | ||
| Q1 24 | $16.6M | $53.8M |
| Q4 25 | $15.7M | — | ||
| Q3 25 | $9.0M | — | ||
| Q2 25 | $6.6M | — | ||
| Q1 25 | $11.1M | — | ||
| Q4 24 | $17.5M | — | ||
| Q3 24 | $10.7M | $-35.5M | ||
| Q2 24 | $20.6M | $-7.3M | ||
| Q1 24 | $15.0M | $53.8M |
| Q4 25 | 15.7% | — | ||
| Q3 25 | 9.2% | — | ||
| Q2 25 | 6.8% | — | ||
| Q1 25 | 12.0% | — | ||
| Q4 24 | 17.6% | — | ||
| Q3 24 | 10.8% | -68.7% | ||
| Q2 24 | 20.0% | -9.9% | ||
| Q1 24 | 15.3% | 39.0% |
| Q4 25 | 0.7% | 0.0% | ||
| Q3 25 | 1.4% | 0.0% | ||
| Q2 25 | 1.4% | 0.0% | ||
| Q1 25 | 1.8% | 0.0% | ||
| Q4 24 | 0.6% | 0.0% | ||
| Q3 24 | 1.1% | 0.3% | ||
| Q2 24 | 2.4% | 0.1% | ||
| Q1 24 | 1.7% | 0.1% |
| Q4 25 | 1.52× | — | ||
| Q3 25 | 0.80× | — | ||
| Q2 25 | 0.81× | — | ||
| Q1 25 | 1.41× | — | ||
| Q4 24 | 1.78× | — | ||
| Q3 24 | 1.15× | — | ||
| Q2 24 | 2.16× | — | ||
| Q1 24 | 1.63× | 0.88× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EBF
Segment breakdown not available.
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
